Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-Specific Mutated Peptide Antigen (TSA/Neoantigen)
- Target
- TSA/Neoantigen
- Molecular classification
- Peptide, Antigen
01
Overview
Tumor-specific mutated peptide antigens, or neoantigens, are unique peptides arising from somatic mutations in cancer cells, not present in normal tissues. They are presented on MHC-I molecules and can be recognized by T-cell receptors, triggering an immune response. They serve as targets for personalized cancer vaccines, adoptive T-cell therapies, and bispecific antibodies. Identification involves sequencing, mutation calling, epitope prediction, and experimental validation.
- Other names
- Tumor-Specific AntigenNeoantigenMutated Peptide Antigen
02
Mechanism of action
Recognition by T-cell receptors, triggering cytotoxic T lymphocyte response against tumor cells
03
Biological functions
Antigen presentationT-cell activationImmune responseTumor cell recognition
04
Disease associations
Cancer
05
Safety considerations
Off-target effects (though minimized due to tumor specificity)Immune-related adverse events (irAEs)Tumor escape mechanisms (e.g., downregulation of MHC-I)
06
Interacting drugs
Personalized cancer vaccines
2 more in the full profile.
07
Biomarkers
Mutation burdenHLA typeTSA expression levelT-cell infiltration
Beyond the preview
Go deeper on Tumor-Specific Mutated Peptide Antigen (TSA/Neoantigen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-Specific Mutated Peptide Antigen (TSA/Neoantigen).